Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease

J Gastroenterol Hepatol. 2021 Aug;36(8):2275-2284. doi: 10.1111/jgh.15487. Epub 2021 Mar 29.

Abstract

Background and aim: Gut microbiota composition is associated with the pathogenesis of non-alcoholic fatty liver disease. However, the association between gut microbiota composition and non-alcoholic fatty liver disease in non-obese patients remains unclear. We compared clinical parameters and gut microbiota profiles of healthy controls and non-obese and obese patients with non-alcoholic fatty liver disease.

Methods: We examined the clinical parameters and gut microbiota profiles by 16S rRNA sequences and short-chain fatty acid levels in fecal samples from 51 non-obese patients with non-alcoholic fatty liver disease (body mass index <25 kg/m2 ) and 51 obese patients with non-alcoholic fatty liver disease (body mass index ≥30 kg/m2 ) who underwent pathological examination and 87 controls at five hospitals in Japan.

Results: Although no significant differences between the non-obese and other groups were observed in alpha diversity, a significant difference was found in beta diversity. We observed a significant decrease in serum alanine aminotransferase levels, Eubacterium population, and butyric acid levels in non-obese patients with non-alcoholic fatty liver disease compared with those in obese patients with non-alcoholic fatty liver disease. A significant negative correlation was found between the stage of hepatic fibrosis and Eubacterium abundance in non-obese patients with non-alcoholic fatty liver disease.

Conclusions: The decrease in the abundance of Eubacterium that produces butyric acid may play an important role in the development of non-alcoholic fatty liver disease in non-obese individuals. This study was registered at the University Hospital Medical Information Network clinical trial registration system (UMIN000020917).

Keywords: Eubacterium; Gut microbiota; Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-obese NAFLD.

MeSH terms

  • Butyric Acid
  • Gastrointestinal Microbiome*
  • Humans
  • Liver
  • Liver Cirrhosis*
  • Non-alcoholic Fatty Liver Disease*
  • Obesity / complications
  • RNA, Ribosomal, 16S

Substances

  • RNA, Ribosomal, 16S
  • Butyric Acid